TerminatedPhase 3NCT05253209
A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
Studying Atrioventricular septal defect
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Asklepion Pharmaceuticals, LLC
- Principal Investigator
- Christopher Mastropietro, MD, FCCMRiley Hospital for Children at Indiana University Health
- Intervention
- L-citrulline(drug)
- Enrollment
- 64 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (10)
- Children's of Alabama, Birmingham, Alabama, United States
- Children's Hospital of Colorado, Aurora, Colorado, United States
- Heart Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
- Cardinal Glennon Children's Hospital, St Louis, Missouri, United States
- Duke University Medical Center Surgical Office of Clinical Research (SOCR), Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital- The Heart Center, Columbus, Ohio, United States
- Seattle Children's Research Institute, Seattle, Washington, United States
- University of Wisconsin-Madison, Madison, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05253209 on ClinicalTrials.govOther trials for Atrioventricular septal defect
Additional recruiting or active studies for the same condition.